Characterization of granulocytic ehrlichia and methods of use
AssigneeAquila Biopharmaceuticals, Inc.
InventorsCheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
Life of this patent
Estimating the term…
Loading patent…
AssigneeAquila Biopharmaceuticals, Inc.
InventorsCheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
Estimating the term…
The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with ehrlichiosis; therapeutic uses, specifically vaccines comprising S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides or nucleic acids; and methods of preventing or inhibiting ehrlichiosis in an animal.
A purified polypeptide comprising an amino acid sequence selected from the group of amino acid sequences set forth as SEQ ID NOS:4, 6, 2, 8, 21, 22, 39, 27, 29, and 30, corresponding to granulocytic Ehrilichia polypeptide S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, or E46#2, respectively.
A purified polypeptide having at least 85% amino acid sequence identity to the amino acid sequence set forth as SEQ ID NO:
A purified polypeptide having at least 90% amino acid sequence identity to the amino acid sequence set forth as SEQ ID NO:
A purified polypeptide comprising (1) at least 6 contiguous amino acids of the amino-terminal consensus sequence shared by granulocytic Ehrlichia polypeptides E8, E46#1, and E46#2;
A purified polypeptide comprising an immunologically reactive fragment of the amino acid sequence set forth as SEQ ID NO:
Dependencies are inferred from the claim text.